Search Results
Jun 22, 2026, 07:00 ET Labcorp Announces Nationwide Availability of ColoSense®, the First FDA-Approved RNA-Based At-Home Colorectal Cancer Screening Test
comprehensive laboratory services, today announced the nationwide availability of ColoSense®, the only RNA-based at-home test for colorectal cancer (CRC) screening approved by the U.S. Food and Drug Administration (FDA). Offered through a commercial collaboration with test developer
More news about: Labcorp
Jun 19, 2026, 10:05 ET Amity University Bengaluru and L&T Technology Services sign a strategic MoU to establish E-mobility Centre of Excellence
University Bengaluru; Dr. Gopalakrishna S. P., Registrar, Amity University Bengaluru and Dr. Tushar Somnathe, Director – Corporate Resource Centre (CRC), Amity University Bengaluru.The collaboration underscores the shared commitment of Amity University Bengaluru and LTTS to building future-ready
More news about: Amity University Bengaluru
Jun 17, 2026, 01:39 ET Ligufalimab (CD47)-Based Combination Achieves Deep Responses and Survival Benefit in Frontline AML: Phase II Results Presented in Oral Session at EHA 2026
the composite complete response (CRc) rate was 56.7% versus 53.3%; the proportion of patients achieving CRc with minimal residual disease (MRD) negativity was higher in the ligufalimab group than in the control group (46.7% vs. 36.7%).The median duration of CRc was 10.4 months in the ligufalimab
More news about: Akeso, Inc.
Jun 15, 2026, 12:31 ET EGFR Inhibitors Market to Witness Upsurge in Growth at a CAGR of 7.9% During the Forecast Period (2026-2036) Owing to the Entry of Next-generation TKIs, ADCs, and Combination Strategies with Immunotherapy| DelveInsight
current treatment practices, addressable patient population, which includes top indications such as Non-small cell lung cancer (NSCLC), Colorectal cancer (CRC), Head and neck cancer (HNC), and others. The selected indications are based on approved therapies and ongoing pipeline activity. The report also provides
More news about: DelveInsight Business Research, LLP
Jun 11, 2026, 02:20 ET CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody) ASCO 2026 Key Highlights
chemotherapy.Q4 2026: FDA discussion regarding Phase III global registrational clinical trial protocol for first-line CRC + chemotherapy.Q4 2026: ESMO Congress – clinical data updates for CRC, NSCLC, and other indications.End of 2026: Initiation of the first-wave global Phase III MRCTs.Importantly,
More news about: CStone Pharmaceuticals
Jun 08, 2026, 05:45 ET Hengrui Pharma Presents More Than 90 Oncology Studies at ASCO 2026, Highlighting Progress Across Multiple Tumor Types
toxicity.Gastrointestinal Cancers: ADC and Immunotherapy Combination Treatments Show PromiseIn the field of colorectal cancer, the HORIZON-CRC01 study led by Professor Jin Li of Shanghai GoBroad Cancer Hospital Affiliated to China Pharmaceutical University and Professor Ying Yuan of The Second
More news about: Hengrui Pharma
Jun 08, 2026, 04:00 ET sweelin® Clinical Trial Results Published in Leading Journal, Food Chemistry, Confirming Blood Glucose Safety
sweetener landscape, directly supporting customer adoption and global expansion. Amai Proteins' study was conducted at the Clinical Research Center (CRC) of Tel Aviv Sourasky Medical Center (Ichilov) under strict Good Clinical Practice (GCP) standards. It tested the effects of sweelin® in a randomized,
More news about: Amai Proteins
Jun 03, 2026, 08:00 ET CRC CEO Tom Zoda, Ph.D., Chairs ASCP 2026 Panel on Preventable Failure Risk in CNS Clinical Trials
Research CorporationCognitive Research Corporation (CRC) is a neuroscience-specialty CRO supporting Phase I-III clinical trials across neurology, psychiatry, and analgesia. With 20 years of exclusive focus on CNS research, CRC combines scientific expertise with operational discipline to deliver
More news about: Cognitive Research Corporation
Jun 02, 2026, 20:00 ET Kelun-Biotech Presents First-in-human Study Data for Its Novel B7-H3 ADC SKB500 at ASCO 2026
those with small cell lung cancer (SCLC), esophageal squamous cell carcinoma (ESCC), head and neck squamous cell carcinoma (HNSCC), colorectal cancer (CRC), neuroendocrine carcinoma (NEC), and other tumors. Patients received SKB500 at doses ranging from 2 to 18 mg/kg every three weeks (Q3W), with dose expansion
More news about: Kelun-Biotech
Jun 02, 2026, 11:30 ET G50 Corp. Confirms Significant Gold and Silver Mineralization in Parallel Veins over 1.3KM at its Golconda Project in Arizona
GRC4016.8 m @4.34 g/t Au, 68.8g/t Ag GDD0913.4 m @1.63g/t Au, 31 g/t Ag (incl. 1.5 m @13.25 g/t Au) GDD0412.2 m @0.56 g/t Au, 200g/t Ag CRC39Gallium is consistent across nearly all holes, continuous from surface in many cases, and occurs over very large vertical intervals, Wallace
More news about: G50 Corp Limited
Jun 01, 2026, 17:57 ET The Inner Circle acknowledges Dr. Jeff T Grange, MD as a Pinnacle Professional Member Inner Circle of Excellence
contributed to books including Sports Medicine Injuries and Emergencies by McGraw Hill Professional and GIS in Hospital and Healthcare Emergency Management by CRC Press.Dr. Grange remains actively engaged in professional and civic service. He serves as a board member with Aeromedevac Air Ambulance and Catalyst
More news about: The Inner Circle
Jun 01, 2026, 07:00 ET Biond Biologics and Guangzhou-Israel Biotechnology Fund ("GIBF") Announce Closing of $8 Million Investment and Collaboration
BND-22 has demonstrated efficacy in heavily treated cancer patients in indications that hardly respond to Immuno-Oncology (IO) therapies, such as MSS-CRC, and is currently being evaluated in an ongoing Phase 2 study at MD Anderson Cancer Center.BND-67 is Biond's next-generation immunotherapy and
More news about: Biond Biologics Ltd.; GIBF
Jun 01, 2026, 01:51 ET Hengrui Pharma Presents More Than 90 Oncology Studies at ASCO 2026, Highlighting Progress Across Multiple Tumor Types
toxicity.Gastrointestinal Cancers: ADC and Immunotherapy Combination Treatments Show PromiseIn the field of colorectal cancer, the HORIZON-CRC01 study led by Professor Jin Li of Shanghai GoBroad Cancer Hospital Affiliated to China Pharmaceutical University and Professor Ying Yuan of The Second
More news about: Hengrui Pharma
May 31, 2026, 20:15 ET ASCO 2026 | CStone Presents Updated Clinical Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody), Reinforcing Triple-Target Synergy and Delivering Strong Proof-of-Concept
was combined with XELOX in first-line mCRC. The current efficacy readout remains immature due to the short follow‑up for most patients in these two CRC cohorts. Additional monotherapy activity was seen in soft tissue sarcoma (STS) and non‑clear cell renal cell carcinoma (nccRCC) (ORR 33.3% each),
More news about: CStone Pharmaceuticals
May 31, 2026, 20:00 ET D3 Bio Presents First-Line Data for Elisrasib (D3S-001) at ASCO 2026; Next-Generation KRAS G12C Inhibitor Shows Landmark Efficacy in Untreated NSCLC
Elisrasib is currently being evaluated globally in a Phase 2 monotherapy and combination trial across KRAS G12C–mutant solid tumors including NSCLC, CRC, and others.Key Publications:Cancer DiscoveryNature Medicine (2025) 31(8):2768–2777About D3 BioD3
More news about: D3 Bio
May 31, 2026, 20:00 ET 2026 ASCO | Innovent Presents Long-Term Follow-up Results from the PoC Study of IBI363 (TAK-928) (PD-1/IL-2α-bias bispecific fusion protein), Showing Robust Survival Benefits in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer
multi-regional Phase III trial in immunotherapy-resistant squamous NSCLC. In parallel, multiple Phase Ib/II trials are evaluating IBI363 in NSCLC and CRC including the first-line and later line settings, and in additional tumor types. IBI363 has received two Fast Track Designations (FTD) from the U.S.
More news about: Innovent Biologics
May 31, 2026, 20:00 ET 2026 ASCO | Innovent Presents Preliminary PoC Data of IBI363 (TAK-928) PD-1/IL-2α-bias bispecific fusion protein) in First-line Advanced NSCLC
multi-regional Phase III trial in immunotherapy-resistant squamous NSCLC. In parallel, multiple Phase Ib/II trials are evaluating IBI363 in NSCLC and CRC including the first-line and later line settings, and in additional tumor types. IBI363 has received two Fast Track Designations (FTD) from the U.S.
More news about: Innovent Biologics
May 29, 2026, 11:00 ET Colorectal Cancer Alliance and GCAR Announce Collaboration to Advance a Groundbreaking Adaptive Clinical Trial Platform for Colorectal Cancer: KLEOS
refers to a person's legacy, honoring those we have lost to CRC and underscoring the need for this project. Through this collaboration, the organizations will accelerate clinical development to bring more effective therapies to patients with CRC faster.
More news about: Global Coalition for Adaptive Research
May 29, 2026, 07:00 ET Labcorp Supports Multi-Institution Trial to Expand Genetic Testing in Colorectal Cancer
Alliance for Clinical Trials in Oncology to advance a national, multicenter clinical trial for patients newly diagnosed with colorectal cancer (CRC). The trial will evaluate approaches to increase germline genetic testing among at-risk family members, as well as the impact of multigene panel testing
More news about: Labcorp
May 27, 2026, 10:14 ET Freenome's SimpleScreen™ CRC Blood-Based Test Included in Updated ACS Colorectal Cancer Screening Guideline
screening participation and patient outcomes."SimpleScreen CRC was submitted for FDA review in August 2025. Approval is expected in mid 2026, and Abbott (formerly Exact Sciences) will lead the broad commercialization of SimpleScreen CRC. The test is currently available at select pilot sites as a laboratory-developed
More news about: Freenome Holdings, Inc.
May 27, 2026, 07:36 ET American Cancer Society Updates Colorectal Cancer Screening Guideline: Major Changes Emphasize Blood-Based and At-Home Stool Testing
CRC Statistics Report 2026
More news about: American Cancer Society
May 27, 2026, 07:01 ET ACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screening
not up to date on CRC screening and improve adherence over time.Proven CRC Screening Impact of Cologuard Enters New Era with Cologuard PlusCologuard tests have transformed colorectal cancer screening, driving an estimated 77% of the nationwide increase in CRC screening participation
More news about: Abbott
May 22, 2026, 08:30 ET Caris Life Sciences to Present 32 Studies at ASCO 2026 Highlighting Advances in Multi-omic Biomarker Research and Real-World Evidence
S403.Posters with Merit Award Mitochondrial DNA (mtDNA) expression as used to define metabolic and immune states in colorectal cancer (CRC). (Abstract 2647) Session: Developmental Therapeutics—Immunotherapy. Date/Time: Saturday, May 30, 2026, 1:30 PM–4:30 PM CDT. Location: Hall A, Poster:
More news about: Caris Life Sciences
May 22, 2026, 00:58 ET 2026 ASCO Abstract Highlights | Innovent Announces Preliminary PoC data of IBI363 (PD-1/IL-2α-bias bispecific fusion protein) in Combination with Chemotherapy as First-line Treatment for Advanced NSCLC, Showing Encouraging Efficacy Signals and Favorable Safety
multi-regional Phase III trial in immunotherapy-resistant squamous NSCLC. In parallel, multiple Phase Ib/II trials are evaluating IBI363 in NSCLC and CRC including the first-line and later line settings, and in additional tumor types. IBI363 has received two Fast Track Designations (FTD) from the U.S.
More news about: Innovent Biologics
May 21, 2026, 19:49 ET 2026 ASCO Abstract Highlights: Innovent Biologics' IBI363 (PD-1/IL-2α-bias bispecific fusion protein) Demonstrates Robust Survival Benefits in Long-Term Follow-up of PoC Study in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer
multi-regional Phase III trial in immunotherapy-resistant squamous NSCLC. In parallel, multiple Phase Ib/II trials are evaluating IBI363 in NSCLC and CRC including the first-line and later line settings, and in additional tumor types. IBI363 has received two Fast Track Designations (FTD) from the U.S.
More news about: Innovent Biologics